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Several noncommunicable diseases have their origins in early developmental phases. One factor possibly explaining the association
between early growth and later health could be adipocyte function.The objective of this study was to assess the association between
the adipocytokine chemerin and early growth and later health. 1074 participants from Helsinki Birth Cohort Study born 1934–
1944 with information on prenatal and childhood growth participated. Metabolic outcomes include glucose tolerance, adiposity,
and chemerin concentration. Mean chemerin concentrations were 5.0 ng/mL higher in women than in men (95% CI 2.7 to 7.2,
𝑝 < 0.001). The strongest correlate of chemerin concentration was adult waist circumference and body fat percentage (𝑟 = 0.22,
𝑝 < 0.001 and 𝑟 = 0.21, 𝑝 < 0.001, resp.). After adjustment for body fat percentage, chemerin concentration was 5.4 ng/mL lower in
subjects with type 2 diabetes than in those with normal glucose tolerance (−0.2 to 10.9, 𝑝 = 0.06). It was 3.0 ng/mL higher in those
with metabolic syndrome than in those without (0.6 to 5.3, 𝑝 = 0.01). No measure of early growth was associated with chemerin
concentration. Our findings do not support a role for chemerin in linking early growth with later metabolic health.
1. Introduction
Several noncommunicable diseases, including type 2 dia-
betes (T2D) and coronary heart disease (CHD), have their
origins in early developmental phases [1]. The intrauterine
environment is largely influenced by maternal diet, maternal
body size, placental function, and hormonal factors that
can affect the fetus via several mechanisms causing life-long
programming of health. Not only prenatal experiences but
also growth and experiences during childhood can have long-
term health consequences [2–4]. We and others have shown
that T2D and CHD are associated with body size at birth but
even more strongly with a mismatch between body size at
birth and body size later in childhood [5, 6].
One possible factor explaining the association between
early growth and later health outcomes could be adipocyte
function and adipocytokine production. Chemerin is a
recently identified adipocytokine shown to be associated
with components of the metabolic syndrome [7–12]. Strong
correlations have been described between chemerin and
several metabolic outcomes including obesity and metabolic
syndrome. Due to the close association between early growth
and these metabolic outcomes chemerin could be one com-
mon denominator explaining these associations. To our
knowledge no previous study has assessed the association
between chemerin concentration and prenatal and childhood
growth and later metabolic health, which was the primary
aim of the present study.
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2016, Article ID 3838646, 6 pages
http://dx.doi.org/10.1155/2016/3838646
2 International Journal of Endocrinology
2. Subjects and Methods
The Helsinki Birth Cohort Study (HBCS) comprises 13345
men and women who were born in one of the two maternity
hospitals in the city between 1934 and 1944 and who attended
child welfare clinics in the city. These clinics were free of
charge and almost all children attended them. The majority
of the children also went to school in the city and had
growth data from school health records available. Details
of the records at birth, in the clinics and at school, have
been described [3, 6]. Each subject had an average of 11
measurements of height and weight from birth to 2 years of
age and 6 measurements of height and weight from 2 to 11
years.Weight and height at age of 20 yearswere obtained from
questionnaire.
We used random number tables to select a subsample
of people who were still alive and living in Finland in the
year 2000 for a clinical study in the years 2001–2003. In
order to achieve a sample size in excess of 2000 people for
this subset we selected 2691 subjects for evaluation. Of these
subjects, 2003 attended a clinical study after an overnight fast.
A follow-up study including 1083 participants was conducted
in the years 2006–2008, focusing upon individuals who were
without manifest type 2 diabetes at the time of the original
study (2001–2003). The exclusion of people with known
diabetes was because one of the study aims was to focus upon
development of diabetes during a 5-year follow-up period in
an elderly group of people. Of these 1074 who had chemerin
concentration measured were included in this study.
Height andweightweremeasured in light indoor clothing
and without shoes with a KaWi stadiometer (nearest 0.1 cm)
and a SECA alpha 770 scale (nearest 0.1 kg), respectively.
Body composition was assessed by bioimpedance using the
In Body 3.0 device. Blood pressure was measured from the
right arm while the subject was in the sitting position, and
it was recorded as the mean of 2 successive readings from
a mercury sphygmomanometer. A 2-hour 75 g oral glucose
tolerance test was performed. Type 2 diabetes and impaired
glucose tolerance were defined using WHO criteria [13].
Glucose was measured according to the hexokinase method.
Plasma insulin concentrations were determined by a two-site
immunometric assay [14, 15]. Serum cholesterol and triglyc-
eride concentrations were measured with the use of standard
enzymatic methods [16, 17]. LDL-cholesterol concentrations
were calculated using the Friedewald formula [18]. Metabolic
syndrome was assessed using the IDF criteria [19]. Chemerin
was measured from serum samples with Millipore’s Human
Chemerin Kit (EZHCMRN.57K) using a Thermo Multiskan
(Thermo Clinical Labsystems Oy, Konelab, Finland).
2.1. Ethical Statement. The study was approved by the Ethics
Committee of Hospital District of Helsinki and Uusimaa and
conducted according to the guidelines of the Declaration of
Helsinki. Written informed consent was obtained from all
subjects.
2.2. Statistical Methods. We analyzed the data using partial
correlation analysis and multiple linear regressions. With
clinic variables, we always included age as a predictor. We
included sex as a predictor in pooled analyses. Triglyceride
and insulin concentrations were right-skewed in distribution
and were log-transformed for analysis.
3. Results
Summary statistics for the adult characteristics of the 1074
subjects are shown in Table 1. Mean chemerin concentrations
were 5.0 ng/mL higher in women than in men (95% confi-
dence interval: 2.7 to 7.2, 𝑝 < 0.001). The strongest correlates
of chemerin concentration were adult body fat percentage
and waist circumference. Adjusting for body fat percentage
explained the association with all other measurements of
current body size except that of waist circumference (Table 1).
Weak positive associations of chemerin concentration with
diastolic blood pressure and fasting glucose concentration
were explained by adjustment for body fat percentage. How-
ever positive associations with triglyceride and fasting insulin
concentrations and a negative association with high density
lipoprotein cholesterol concentration remained after such
adjustment (Table 1).
Summary statistics for the maternal, neonatal, and child-
hood characteristics of the subjects are shown in Table 2. No
measure of maternal, neonatal, infant, or childhood anthro-
pometry was associated with chemerin concentration, either
with or without adjustment for adult body fat percentage
(Table 2). Nor was there any association with gestational age
at delivery,with head circumference, orwith placentalweight.
Table 3 shows mean levels of chemerin concentration
in men and women according to their glucose tolerance
status and the presence of the metabolic syndrome. After
adjustment for body fat percentage and pooling across men
and women, chemerin concentration was 5.4 ng/mL lower
in subjects with type 2 diabetes than in those with normal
glucose tolerance (−0.2 to 10.9, 𝑝 = 0.06), and it was
3.0 ng/mL higher in those with metabolic syndrome (IDF
criteria) than in those without (0.6 to 5.3, 𝑝 = 0.01).
4. Discussion
Several noncommunicable diseases including T2D and CHD
have been shown to be associated with markers of early
growth [1–6]. Chemerin, a recently identified adipocytokine,
has been suggested to be associated with prenatal growth,
as well as being a strong marker of insulin resistance and
the metabolic syndrome [7–12, 20, 21]. In the present study
chemerin was strongly and positively associated with adipos-
ity in adult life especially with body fat percentage and waist
circumference. Women had higher chemerin concentrations
than men. When adjusting for body fat percentage chemerin
concentrations were higher in those with the metabolic syn-
drome but lower among those with manifest type 2 diabetes.
Due to the close association between early growth and several
metabolic and adiposity related outcomes chemerin could be
one potential denominator explaining these associations. We
did not find any association between prenatal or childhood
growth and chemerin concentrations in adult life. Therefore
our findings do not support a major role for chemerin in
linking early growth with later metabolic health.
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Table 1: Descriptive data for adult clinical measurements and correlations with chemerin concentration.
Adult clinical measurements
Men
(𝑛 = 480)
Women
(𝑛 = 594) Correlation with chemerin concentration
Mean (SD) Mean (SD) Direct‡ Adjusted†
Age (years) 61.5 (2.7) 61.6 (3.0) — —
Height (cm) 177.0 (6.0) 163.5 (5.7) −0.04 0.01
Weight (kg) 84.7 (12.1) 72.4 (12.2) 0.15∗∗∗ 0.01
BMI (kg/m2) 27.0 (3.5) 27.1 (4.4) 0.18∗∗∗ 0.01
Waist circumference (cm) 99.0 (10.3) 89.4 (11.3) 0.22∗∗∗ 0.09∗∗
Lean body mass (kg) 65.0 (7.2) 47.6 (5.4) 0.07∗ 0.03
Fat mass (kg) 19.7 (7.2) 24.5 (8.3) 0.19∗∗∗ 0.00
Body fat percentage (%) 22.8 (5.6) 33.2 (6.4) 0.21∗∗∗ —
Systolic blood pressure (mmHg) 144.3 (18.5) 142.0 (20.2) 0.03 −0.01
Diastolic blood pressure (mmHg) 89.7 (9.9) 86.8 (9.9) 0.06∗ 0.01
Total cholesterol (mmol/L) 5.8 (1.0) 6.0 (1.0) 0.02 0.01
Triglyceride (mmol/L)Δ 1.5 (0.8) 1.4 (0.7) 0.19∗∗∗ 0.13∗∗∗
HDL cholesterol (mmol/L) 1.5 (0.4) 1.8 (0.4) −0.15∗∗ −0.10∗∗
LDL cholesterol (mmol/L) 3.7 (0.8) 3.7 (0.9) 0.03 0.01
Fasting glucose (mmol/L) 5.7 (0.6) 5.4 (0.6) 0.09∗∗ 0.05
Fasting insulin (pmol/L)Δ 10.2 (7.0) 9.2 (10.4) 0.15∗∗∗ 0.07∗
Chemerin (ng/mL) 66.2 (17.7) 71.2 (19.1) 1.00 1.00
‡Adjusted for age at clinic and sex. †Adjusted for age at clinic, sex, and adult body fat percentage.
ΔVariable log-transformed for analysis. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
A recent meta-analysis concluded that chemerin con-
centrations in obese subjects and in subjects with metabolic
syndrome seem to be associated with obesity and distur-
bances in lipid, glucose, and insulin metabolism [12]. In
the present study there was a strong association between
different measures of adiposity in adult life and chemerin
concentrations.Women had higher chemerin concentrations
than men, probably as a consequence of higher body fat per-
centage. Also, individuals with MS had significantly higher
chemerin concentrations. This is consistent with previous
studies. There have even been suggestions that chemerin
might play a role in the development of obesity and MS [7–
12, 22, 23]. Some previous studies, but not all, have reported
elevated levels of chemerin in T2D subjects [7, 23]. In the
present study we report lower chemerin levels in people with
T2D. One reason could be the fact that we were able to
adjust for adult body composition. Another reason could
be that our study included only recently diagnosed T2D
subjects, due to the study design. This might have major
impact on the results since some diabetes drugs are known to
affect chemerin concentration. Increased levels of chemerin,
occurring in association with obesity, have been proposed
to be one factor in the development of type 2 diabetes.
It has in fact been suggested that chemerin might present
either inhibitory or stimulatory effects on glucose uptake
through various mechanisms, for example, through glucose-
stimulated insulin secretion [24]. In other words published
studies on chemerin concentration in type 2 diabetic subjects
are inconsistent possibly due to the heterogenous nature
of type 2 diabetes, possible impact of diabetes drugs, and
disease duration. Only longitudinal studies are able to assess
whether the association between themetabolic syndrome and
chemerin will reverse when manifest type 2 diabetes devel-
ops. Supporting the present findings decreased chemerin
levels have also been reported in women with gestational
diabetes. It has been suggested that this contributes to
the insulin resistance associated with GDM [25]. Elevated
chemerin concentrations have also been reported in subjects
with CHD, dyslipidemia, and inflammatory states, all closely
associated with the metabolic syndrome and T2D [26–31].
Chemerin is expressed in the placenta and also secreted
by the placenta emphasizing its role in controlling several
metabolic processes during pregnancy. Increased chemerin
levels are seen especially during late gestation supporting
a role for chemerin in fetal growth [20, 21, 32]. Higher
chemerin concentrations have been reported in cord blood
from obese women. Consequently higher chemerin concen-
trations in cord blood samples of large size neonates have
also been reported [33]. Maternal serum chemerin levels
also differed between preeclamptic and healthy pregnant
women, increasing with the severity of preeclampsia [34,
35]. Besides regulating fetomaternalmetabolism, a significant
increase of chemerin has been observed in polycystic ovary
syndrome [36]. We did not find any significant associations
between maternal, prenatal, placental, infant, or childhood
growth and characteristics and chemerin concentrations in
adult life. However, chemerin concentration was strongly
associated with adiposity. We have previously shown that
prenatal growth is more strongly associated with lean body
mass than with fat mass [37]. This could be one reason
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Table 2: Descriptive data for maternal, neonatal, and childhood measurements and correlations with chemerin concentration.
Maternal, neonatal, and
childhood measurements
Men
(𝑛 = 480)
Women
(𝑛 = 594) Correlation with chemerin concentration
Mean (SD) Mean (SD) Direct‡ Adjusted†
Maternal measurements
Age (years) 28.8 (5.4) 28.7 (5.4) −0.01 −0.00
Height (cm) 159.6 (6.0) 159.6 (5.6) 0.02 0.04
Weight (kg) 67.2 (7.6) 67.4 (8.0) −0.01 −0.01
BMI (kg/m2) 26.4 (2.8) 26.4 (2.8) −0.02 −0.03
Neonatal measurements
Gestational age (days) 297 (11) 280 (11) −0.00 −0.01
Birth weight (g) 3485 (480) 3363 (458) −0.03 −0.02
Birth length (cm) 50.7 (2.0) 50.1 (1.9) −0.02 −0.00
Head circumference (cm) 35.5 (1.5) 34.9 (1.4) −0.02 −0.03
Ponderal index (kg/m3) 26.7 (2.4) 26.7 (2.2) −0.02 −0.03
Placental weight (g) 661 (119) 644 (121) −0.05 −0.05
Childhood measurements
Age 1 year
Height (cm) 76.7 (2.5) 75.1 (2.5) 0.01 0.03
Weight (kg) 10.5 (1.0) 9.9 (1.0) 0.02 0.02
BMI (kg/m2) 17.9 (1.4) 17.6 (1.4) 0.02 0.01
Age 2 years
Height (cm) 86.8 (3.0) 85.8 (3.0) 0.01 0.03
Weight (kg) 12.5 (1.1) 12.0 (1.1) 0.01 0.02
BMI (kg/m2) 16.7 (1.2) 16.5 (1.2) 0.01 0.00
Age 7 years
Height (cm) 121.0 (4.8) 120.3 (4.6) 0.01 0.03
Weight (kg) 22.6 (2.6) 22.4 (2.8) 0.02 0.03
BMI (kg/m2) 15.5 (1.1) 15.5 (1.3) 0.03 0.01
Age 11 years
Height (cm) 141.7 (5.7) 141.7 (6.5) −0.01 0.01
Weight (kg) 33.8 (4.4) 34.3 (5.6) 0.03 0.02
BMI (kg/m2) 16.8 (1.4) 17.1 (1.9) 0.05 0.02
Age 20 years
Height (cm) 177.0 (6.0) 163.5 (5.7) −0.04 0.01
Weight (kg) 70.9 (8.0) 56.2 (6.8) 0.01 −0.01
BMI (kg/m2) 22.6 (2.2) 21.0 (2.4) 0.05 −0.01
‡Adjusted for age at clinic and sex. †Adjusted for age at clinic, sex and adult body fat percentage.
No correlations were statistically significant at the 5% level.
why no association between early growth and chemerin
concentrations was observed.
There are some limitations to our study. Since the
follow-up study in 2006–2008 primarily included individuals
without diabetes in 2001–2003, we are studying primarily
nondiabetic representatives of the age group of 62 to 74
years, including recently diagnosed type 2 diabetic subjects.
Our cohort only includes individuals born in Helsinki
who attended child welfare clinics in the city and might
therefore not be representative of the Finnish population.
However, socioeconomic status birth, defined as father’s
highest attained occupational status, was comparable to
the contemporary Helsinki population. All subjects were
born and/or grew up during World War II, which might
have influenced both nutritional status and growth during
childhood. The results, therefore, might not be generalizable
to children born and growing up today, but we see no reason
why this would influence chemerin concentrations. Finally
we do not have information of body composition at birth and
during childhood in the elderly population. This is certainly
one limitation since it is possible that body composition at
birth might have long-term health consequences.
We conclude that chemerin concentrations are strongly
associated with adiposity among elderly subjects. Prenatal,
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Table 3: Chemerin concentration according to glucose tolerance or metabolic syndrome in men and women.
Chemerin concentration (ng/mL)
Men Women
𝑛 Mean (SD) 𝑝 value† 𝑛 Mean (SD) 𝑝 value†
Glucose tolerance‡
Normal 336 66.5 (17.8) Baseline 409 70.7 (19.5) Baseline
Impaired 118 66.3 (17.8) 0.4 165 72.7 (18.2) 0.9
Type 2 diabetes 26 62.0 (15.0) 0.1 18 67.0 (15.6) 0.3
Metabolic syndrome‡
Absent 185 63.9 (17.2) Baseline 335 68.4 (18.0) Baseline
Present 294 67.5 (17.8) 0.2 259 74.8 (19.8) 0.03
All subjects 480 66.2 (17.7) 594 71.2 (19.1)
†Adjusted for age and body fat percentage and compared to normal glucose tolerance or no metabolic syndrome groups.
‡Glucose tolerance not known for two women; metabolic syndrome status not known for one man.
placental, infant, and childhood characteristics and growth
measurements were not associated with chemerin concentra-
tions. Our findings do not support a major role for chemerin
in linking early growthwith latermetabolic health. Chemerin
appears to be amarker of adiposity and body fatmass and this
should be taken into account in further studies on chemerin
and its function in metabolism.
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